Replimune (NASDAQ:REPL) announces new data from a Phase 1/2 clinical trial evaluating the combination of lead candidate RP1 and Bristol-Myers Squibb’s (NYSE:BMY) Opdivo (nivolumab) in patients with solid tumors.
Preliminary results from the 30-subject
non-melanoma skin cancer cohort showed positive action. At data cutoff,
the response rate was 86% (n=6/7) including a 57% (n=4/7) complete
response rate.
Overall, 36 melanoma patients have been treated.
Five have “met the formal criteria for response.” Four of the five
failed to respond to prior anti-PD-1 and anti-CTLA-4 therapies.
Its 240-subject Phase 2 study evaluating the combination of RP1 and Regeneron (NASDAQ:REGN) and Sanofi’s (NASDAQ:SNY) Libtayo (cemiplimab-rwlc) in cutaneous squamous cell carcinoma patients, CERPASS, is currently recruiting participants.
RP1 is based on a strain of herpes simplex virus
engineered to maximize the anti-cancer effect and activate a systemic
anti-tumor immune response.
Management hosted a conference call this morning at 8:00 am ET to discuss the data.
https://seekingalpha.com/news/3579961-replimune-lead-drug-shows-benefit-in-non-melanoma-skin-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.